


# The right prevention and treatment for the right patient at the right time

Strategic Research Agenda for  
Innovative Medicines Initiative 2

**MUDr. Richard Imrich, DrSc.**

Národný delegát - Zdravie, demografické  
zmeny a kvalita života





# Innovative Medicines Initiative 2: Europe's fast track to better medicines

## IMI2 IS A JOINT TECHNOLOGY INITIATIVE (JTI)

- NEXT GENERATION VACCINES, MEDICINES AND TREATMENTS, E.G. NEW ANTIBIOTICS;
- FASTER ROLL-OUT OF EFFECTIVE AND SUSTAINABLE HEALTHCARE;
- LEVERAGING PUBLIC AND PRIVATE RESEARCH FUNDING TO LOWER INVESTMENT BARRIERS;
- SUPPORTING THE GLOBAL COMPETITIVENESS OF EUROPE'S PHARMACEUTICAL INDUSTRY


# Goals of IMI 2

- ▶ a 30% better success rate in clinical trials of priority medicines identified by the WHO;
- ▶ clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in just five years;
- ▶ new and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer's disease

# Budget and Duration

- ▶ The total budget proposed for IMI 2 is **€3.3 billion**.
- ▶ The **EU** will contribute up to **€1.6 billion** of this from **Horizon 2020**, the EU research and innovation framework programme.
- ▶ **EFPIA**, the European Federation of Pharmaceutical Industries and Associations, will commit **€1.6 billion in in kind contributions**.
- ▶ In addition, **other life science industries** may contribute a further **€225 million** if they decide to join IMI 2 as members or as partners in individual projects.
- ▶ IMI 2 will start in 2014 and will run for **10 years**.

# Major Axis of Research



**DRIVE CHANGE IN DELIVERY OF MEDICAL PRACTICE**

# Strategic Research Agenda

Antimicrobial resistance

Osteoarthritis

Cardiovascular diseases

Diabetes

Neurodegenerative diseases

Psychiatric diseases

Respiratory diseases

Immune-mediated diseases

Ageing-associated diseases

Cancer

Rare/Orphan Diseases

Vaccines



**Axis 1: Target validation and biomarker development**

**Axis 2: Adoption of innovative clinical trial paradigms**

**Axis 3: Innovative Medicines**

**Axis 4: Patient tailored adherence programmes**

# Ďakujem za pozornosť

- ▶ Národný delegát: Richard Imrich [richard.Imrich@savba.sk](mailto:richard.Imrich@savba.sk)
- ▶ Národný kontaktný bod: Iveta Hermanovská [iveta.hermanovska@cvtisr.sk](mailto:iveta.hermanovska@cvtisr.sk)